Do analysts prefer PAVM or ZJYL?

PAVmed presently has a consensus target price of $56.00, indicating a potential upside of 1,044.02%. Given PAVmed's stronger consensus rating and higher possible upside, equities analysts plainly believe PAVmed is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PAVM or ZJYL?

Jin Medical International has higher revenue and earnings than PAVmed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 69.93 $400K -$37.40 N/A Jin Medical International $20.69M 0.86 $1.19M N/A N/A

Is PAVM or CODX more profitable?

Co-Diagnostics has a net margin of -6,760.63% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media refer more to PAVM or CODX?

In the previous week, PAVmed had 10 more articles in the media than Co-Diagnostics. MarketBeat recorded 13 mentions for PAVmed and 3 mentions for Co-Diagnostics. PAVmed's average media sentiment score of 0.91 beat Co-Diagnostics' score of 0.30 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, FEMY or PAVM?

PAVmed has lower revenue, but higher earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.38M 5.04 -$18.63M -$5.40 N/A PAVmed $70K 69.93 $400K -$37.40 N/A

Is FEMY or PAVM more profitable?

Femasys has a net margin of -521.97% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% PAVmed -21,914.12% -146.19% -18.39%

Does the media prefer FEMY or PAVM?

In the previous week, PAVmed had 10 more articles in the media than Femasys. MarketBeat recorded 13 mentions for PAVmed and 3 mentions for Femasys. PAVmed's average media sentiment score of 0.91 beat Femasys' score of 0.22 indicating that PAVmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PAVmed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, PAVM or HIND?

PAVmed has higher earnings, but lower revenue than Vyome. Vyome is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 69.93 $400K -$37.40 N/A Vyome $320K 50.24 -$10.26M -$12.27 N/A

Is PAVM or HIND more profitable?

Vyome has a net margin of -270.58% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% Vyome -270.58% -203.92% -134.16%

Does the media refer more to PAVM or HIND?

In the previous week, PAVmed had 10 more articles in the media than Vyome. MarketBeat recorded 13 mentions for PAVmed and 3 mentions for Vyome. Vyome's average media sentiment score of 1.28 beat PAVmed's score of 0.91 indicating that Vyome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vyome 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PAVM or OSRH?

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 1,044.02%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PAVM or OSRH?

PAVmed has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 69.93 $400K -$37.40 N/A OSR $2.63M 5.13 -$27.06M -$0.33 N/A

Is PAVM or OSRH more profitable?

OSR has a net margin of -363.26% compared to PAVmed's net margin of -21,914.12%. OSR's return on equity of -7.24% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% OSR -363.26% -7.24% -5.41%

Does the media refer more to PAVM or OSRH?

In the previous week, PAVmed had 11 more articles in the media than OSR. MarketBeat recorded 13 mentions for PAVmed and 2 mentions for OSR. OSR's average media sentiment score of 0.93 beat PAVmed's score of 0.91 indicating that OSR is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OSR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PAVmed (PAVM) Competitors

$4.89 -0.11 (-2.10%)

As of 11:22 AM Eastern

Compare

PAVM vs. ZJYL, CODX, FEMY, HIND, and OSRH

Should you buy PAVmed stock or one of its competitors? MarketBeat compares PAVmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PAVmed include Jin Medical International (ZJYL), Co-Diagnostics (CODX), Femasys (FEMY), Vyome (HIND), and OSR (OSRH). These companies are all part of the "medical equipment" industry.

How does PAVmed compare to Jin Medical International?

PAVmed (NASDAQ:PAVM) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Jin Medical International has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Jin Medical International's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Jin Medical International	N/A	N/A	N/A

PAVmed has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.24, indicating that its share price is 624% more volatile than the broader market.

19.9% of PAVmed shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, PAVmed had 12 more articles in the media than Jin Medical International. MarketBeat recorded 13 mentions for PAVmed and 1 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.87 beat PAVmed's score of 0.91 indicating that Jin Medical International is being referred to more favorably in the news media.

Company	Overall Sentiment
PAVmed	Positive
Jin Medical International	Very Positive

Jin Medical International has higher revenue and earnings than PAVmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	69.93	$400K	-$37.40	N/A
Jin Medical International	$20.69M	0.86	$1.19M	N/A	N/A

PAVmed presently has a consensus target price of $56.00, indicating a potential upside of 1,044.02%. Given PAVmed's stronger consensus rating and higher possible upside, equities analysts plainly believe PAVmed is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PAVmed and Jin Medical International tied by winning 7 of the 14 factors compared between the two stocks.

How does PAVmed compare to Co-Diagnostics?

PAVmed (NASDAQ:PAVM) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

PAVmed has higher earnings, but lower revenue than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	69.93	$400K	-$37.40	N/A
Co-Diagnostics	$620K	24.10	-$46.90M	-$15.77	N/A

PAVmed has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.7, meaning that its share price is 170% more volatile than the broader market.

Co-Diagnostics has a net margin of -6,760.63% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

In the previous week, PAVmed had 10 more articles in the media than Co-Diagnostics. MarketBeat recorded 13 mentions for PAVmed and 3 mentions for Co-Diagnostics. PAVmed's average media sentiment score of 0.91 beat Co-Diagnostics' score of 0.30 indicating that PAVmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.9% of PAVmed shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 1,044.02%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 1,566.67%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than PAVmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PAVmed beats Co-Diagnostics on 9 of the 14 factors compared between the two stocks.

How does PAVmed compare to Femasys?

Femasys (NASDAQ:FEMY) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Femasys has a beta of -2.23, meaning that its stock price is 323% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Femasys has a net margin of -521.97% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
PAVmed	-21,914.12%	-146.19%	-18.39%

In the previous week, PAVmed had 10 more articles in the media than Femasys. MarketBeat recorded 13 mentions for PAVmed and 3 mentions for Femasys. PAVmed's average media sentiment score of 0.91 beat Femasys' score of 0.22 indicating that PAVmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PAVmed has lower revenue, but higher earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	5.04	-$18.63M	-$5.40	N/A
PAVmed	$70K	69.93	$400K	-$37.40	N/A

65.3% of Femasys shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 7.6% of Femasys shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Femasys currently has a consensus price target of $106.67, suggesting a potential upside of 2,591.56%. PAVmed has a consensus price target of $56.00, suggesting a potential upside of 1,044.02%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts clearly believe Femasys is more favorable than PAVmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PAVmed beats Femasys on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to Vyome?

PAVmed (NASDAQ:PAVM) and Vyome (NASDAQ:HIND) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

PAVmed has higher earnings, but lower revenue than Vyome. Vyome is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	69.93	$400K	-$37.40	N/A
Vyome	$320K	50.24	-$10.26M	-$12.27	N/A

PAVmed has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Vyome has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Vyome has a net margin of -270.58% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Vyome	-270.58%	-203.92%	-134.16%

PAVmed currently has a consensus target price of $56.00, suggesting a potential upside of 1,044.02%. Vyome has a consensus target price of $15.00, suggesting a potential upside of 555.02%. Given PAVmed's higher possible upside, equities analysts plainly believe PAVmed is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, PAVmed had 10 more articles in the media than Vyome. MarketBeat recorded 13 mentions for PAVmed and 3 mentions for Vyome. Vyome's average media sentiment score of 1.28 beat PAVmed's score of 0.91 indicating that Vyome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vyome	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vyome beats PAVmed on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to OSR?

PAVmed (NASDAQ:PAVM) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

PAVmed has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, OSR has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

19.9% of PAVmed shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 36.8% of OSR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PAVmed has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	69.93	$400K	-$37.40	N/A
OSR	$2.63M	5.13	-$27.06M	-$0.33	N/A

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 1,044.02%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OSR has a net margin of -363.26% compared to PAVmed's net margin of -21,914.12%. OSR's return on equity of -7.24% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
OSR	-363.26%	-7.24%	-5.41%

In the previous week, PAVmed had 11 more articles in the media than OSR. MarketBeat recorded 13 mentions for PAVmed and 2 mentions for OSR. OSR's average media sentiment score of 0.93 beat PAVmed's score of 0.91 indicating that OSR is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OSR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OSR beats PAVmed on 9 of the 16 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.90M	$7.06B	$6.50B	$12.32B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	-0.13	48.29	24.00	24.65
Price / Sales	69.93	85.57	543.88	171.03
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	-2.02	6.90	10.73	6.84
Net Income	$400K	$159.20M	$3.56B	$337.45M
7 Day Performance	-5.50%	-0.46%	1.34%	2.48%
1 Month Performance	-25.04%	5.51%	2.25%	4.36%
1 Year Performance	-74.45%	2.40%	26.20%	32.45%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAVM PAVmed	3.3997 of 5 stars	$4.90 -2.1%	$56.00 +1,044.0%	-73.9%	$4.90M	$70K	N/A	90	News Coverage Short Interest Decrease Analyst Revision
ZJYL Jin Medical International	1.3282 of 5 stars	$2.29 +1.8%	N/A	-82.3%	$17.93M	$20.69M	N/A	245	Positive News
CODX Co-Diagnostics	2.0528 of 5 stars	$4.50 -10.9%	$67.50 +1,400.0%	-48.2%	$16.61M	$620K	N/A	100	Short Interest Increase Gap Down
FEMY Femasys	2.0663 of 5 stars	$5.25 -2.6%	$106.67 +1,931.7%	-76.5%	$15.86M	$2.38M	N/A	30	Analyst Upgrade Short Interest Increase Gap Up
HIND Vyome	3.5192 of 5 stars	$2.11 -3.7%	$15.00 +610.9%	N/A	$14.81M	$152.72K	N/A	50	News Coverage Positive News Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors

PAVM vs. ZJYL, CODX, FEMY, HIND, and OSRH

How does PAVmed compare to Jin Medical International?

Summary

How does PAVmed compare to Co-Diagnostics?

Summary

How does PAVmed compare to Femasys?

Summary

How does PAVmed compare to Vyome?

Summary

How does PAVmed compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PAVmed (PAVM) Competitors

PAVM vs. ZJYL, CODX, FEMY, HIND, and OSRH

How does PAVmed compare to Jin Medical International?

Is PAVM or ZJYL more profitable?

Which has more risk and volatility, PAVM or ZJYL?

Do institutionals and insiders believe in PAVM or ZJYL?

Does the media prefer PAVM or ZJYL?

Which has better valuation & earnings, PAVM or ZJYL?

Do analysts prefer PAVM or ZJYL?

Summary

How does PAVmed compare to Co-Diagnostics?

Which has higher valuation and earnings, PAVM or CODX?

Which has more risk and volatility, PAVM or CODX?

Is PAVM or CODX more profitable?

Does the media refer more to PAVM or CODX?

Do insiders and institutionals hold more shares of PAVM or CODX?

Do analysts rate PAVM or CODX?

Summary

How does PAVmed compare to Femasys?

Which has more risk and volatility, FEMY or PAVM?

Is FEMY or PAVM more profitable?

Does the media prefer FEMY or PAVM?

Which has better earnings & valuation, FEMY or PAVM?

Do insiders and institutionals have more ownership in FEMY or PAVM?

Do analysts recommend FEMY or PAVM?

Summary

How does PAVmed compare to Vyome?

Which has better valuation & earnings, PAVM or HIND?

Which has more risk & volatility, PAVM or HIND?

Is PAVM or HIND more profitable?

Do analysts rate PAVM or HIND?

Does the media refer more to PAVM or HIND?

Do institutionals & insiders hold more shares of PAVM or HIND?

Summary

How does PAVmed compare to OSR?

Which has more risk & volatility, PAVM or OSRH?

Do insiders and institutionals believe in PAVM or OSRH?

Which has better earnings and valuation, PAVM or OSRH?

Do analysts prefer PAVM or OSRH?

Is PAVM or OSRH more profitable?

Does the media refer more to PAVM or OSRH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools